Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

This study has been completed.
Sponsor:
Information provided by:
International Extranodal Lymphoma Study Group (IELSG)
ClinicalTrials.gov Identifier:
NCT00210314
First received: September 13, 2005
Last updated: March 27, 2015
Last verified: March 2015